Six Life Science Bets For 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
2014 is not even a week old, but several privately-held companies have made resolutions to enter the public market this year, building on the momentum of a strong IPO market in 2013.
You may also be interested in...
Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.